SESSION 1993

SENATE BILL 622 Insurance Committee Substitute Adopted 5/10/93 Third Edition Engrossed 5/12/93

Short Title: Misc. Health Ins. Amendments.

Sponsors:

Referred to:

March 29, 1993

1	A BILL TO BE ENTITLED
2	AN ACT TO MAKE MISCELLANEOUS AMENDMENTS TO LAWS GOVERNING
3	HEALTH INSURANCE.
4	The General Assembly of North Carolina enacts:
5	Section 1. G.S. 58-3-150(b) reads as rewritten:
6	"(b) As With respect to group and blanket accident and health insurance and
7	insurance, group life insurance insurance, and group annuity policies issued and
8	delivered to a trust or to an association outside of this State and covering persons
9	resident in this State, the group certificates to be delivered or issued for delivery in this
10	State shall be filed with and approved by the Commissioner pursuant to subsection (a)
11	of this section."
12	Sec. 2. Article 3 of Chapter 58 of the General Statutes is amended by adding
13	a new section to read:
14	" <u>§ 58-3-170. Requirements for maternity coverage.</u>
15	(a) Every entity providing a health benefit plan that provides maternity coverage
16	in this State shall provide benefits for the necessary care and treatment related to
17	maternity that are no less favorable than benefits for physical illness generally.
18	(b) As used in this section, 'health benefit plans' means accident and health
19	insurance policies or certificates; nonprofit hospital or medical service corporation
20	contracts; health, hospital, or medical service corporation plan contracts; health

S

(Public)

3

maintenance organization (HMO) subscriber contracts; and plans provided by a MEWA or plans provided by other benefit arrangements, to the extent permitted by ERISA." Sec. 3. G.S. 58-58-145 reads as rewritten: "§ 58-58-145. Group annuity contracts defined; requirements. Any policy or contract, except a joint, reversionary or survivorship annuity contract, whereby annuities are payable dependent upon the continuation of the lives of to more than one person, shall be deemed is a group annuity contract. The person, firm or corporation to whom or to which such contract is issued, as herein provided, shall be deemed is the holder of such the contract. The term 'annuitant' as used herein, refers to means any person upon whose continued life such annuity is dependent. to whom or which payments are made under the group annuity contract. No authorized insurer shall deliver or issue for delivery in this State any group annuity contract except upon a group of annuitants which that conforms to the following: under a contract issued to an employer, or to the trustee of a fund established by an employer or two or more employers in the same industry or kind of business, the stipulated payments on which

16 shall be paid by the holder of such contract either wholly from the employer's funds or 17 funds contributed by him, or partly from such funds and partly from funds contributed 18 by the employees covered by such contract, and providing a plan of retirement annuities under a plan which permits all of the employees of such employer or of any specified 19 20 class or classes thereof to become annuitants. Any such group of employees may 21 include retired employees, and may include officers and managers as employees, and may include the employees of subsidiary or affiliated corporations of a corporation 22 23 employer, and may include the individual proprietors, partners and employees of affiliated individuals and firms controlled by the holders through stock ownership, 24 25 contract or otherwise."

26

1 2

3

4 5

6

7

8

9

10

11 12

13 14

15

Sec. 4. G.S. 58-51-15(a) reads as rewritten:

27 Required Provisions. - Except as provided in subsection (c) of this section "(a) 28 each such policy delivered or issued for delivery to any person in this State shall contain 29 the provisions specified in this subsection in the substance of the words that appear in 30 this section. Such provisions shall be preceded individually by the caption appearing in this subsection or, at the option of the insurer, by such appropriate individual or group 31 captions or subcaptions as the Commissioner may approve. 32 A provision in the substance of the following language:

33 34 (1)

35 36

37

38 39

40 41

42

43

44

A provision in the substance of the following language: (2)

to change this policy or waive any of its provisions.

- TIME LIMIT ON CERTAIN DEFENSES:
 - After two years from the date of issue or reinstatement of this a. policy no misstatements except fraudulent misstatements made by the applicant in the application for such policy shall be used

ENTIRE CONTRACT; CHANGES: This policy, including the

endorsements and the attached papers, if any, constitutes the entire

contract of insurance. No change in this policy shall be valid until approved by an executive officer of the insurer and unless such

approval be endorsed hereon or attached hereto. No agent has authority

	1993		GENERAL ASSEMBLY OF NORTH CAROLINA
1			to void the policy or deny a claim for loss incurred or disability
2			(as defined in the policy) commencing after the expiration of
3			such two-year period.
4			The foregoing policy provisions may be used in its entirety
5			only in major or catastrophe hospitalization policies and major
6			medical policies each affording benefits of five thousand dollars
7			(\$5,000) or more for any one sickness or injury. Disability
8			income policies affording benefits of one hundred dollars
9			(\$100.00) or more per month for not less than 12 months and
10			franchise policies. Other policies to which this section applies
11			must delete the words 'except fraudulent misstatements.'
12			(The foregoing policy provision shall not be so construed as to
13			affect any legal requirement for avoidance of a policy or denial of a
14			claim during such initial two-year period, nor to limit the application
15			of G.S. 58-51-15(b), (1), (2), (3), (4) and (5) in the event of
16			misstatement with respect to age or occupation or other insurance.)
17			(A policy which the insured has the right to continue in
18			force subject to its terms by the timely payment of premium:
19			1. Until at least age 50 or,
20			2. In the case of a policy issued after age 44, for at least
21			five years from its date of issue, may contain in lieu of
22			the foregoing the following provisions (from which the
23			clause in parentheses may be omitted at the insurer's
24 25			option) under the caption 'INCONTESTABLE.'
23 26			After this policy has been in force for a period of two years during the lifetime of the insured (excluding any period
20 27			during which the insured is disabled), it shall become
28			incontestable as to the statements contained in the application.)
20 29			b. No claim for loss incurred or disability (as defined in the
30			policy) commencing after two years from the date of issue of
31			this policy shall be reduced or denied on the ground that a
32			disease or physical condition not excluded from coverage by
33			name or specific description effective on the date of loss had
34			existed prior to the effective date of coverage of this policy.
35		(3)	A provision in the substance of the following language:
36		. /	GRACE PERIOD: A grace period of (insert a number not
37			less than '7' for weekly premium policies, '10' for monthly premium
38			policies and '31' for all other policies) days will be granted for the
39			payment of each premium falling due after the first premium, during
40			which grace period the policy shall continue in force.
41			(A policy which contains a cancellation provision may add, at the
42			end of the above provision, subject to the right of the insurer to cancel
43			in accordance with the cancellation provision hereof.

1		A policy in which the insurer reserves the right to refuse any
2		renewal shall have, at the beginning of the above provision,
3		Unless not less than five days prior to the premium due date the
4		insurer has delivered to the insured or has mailed to his last address as
5		shown by the record of the insurer written notice of its intention not to
6		renew this policy beyond the period for which the premium has been
7		accepted.)
8	(4)	A provision in the substance of the following language:
9		REINSTATEMENT: If any renewal premium be not paid within
10		the time granted the insured for payment, a subsequent acceptance of
11		premium by the insurer or by any agent duly authorized by the insurer
12		to accept such premium, without requiring in connection therewith an
13		application for reinstatement, shall reinstate the policy; provided,
14		however, that if the insurer or such agent requires an application for
15		reinstatement and issues a conditional receipt for the premium
16		tendered, the policy will be reinstated upon approval of such
17		application by the insurer, or, lacking such approval, upon the forty-
18		fifth day following the date of such conditional receipt unless the
19		insurer has previously notified the insured in writing of its disapproval
20		of such application. The reinstated policy shall cover only loss
21		resulting from such accidental injury as may be sustained after the date
22		of reinstatement and loss due to such sickness as may begin more than
23		10 days after such date. In all other respects the insured and insurer
24		shall have the same rights thereunder as they had under the policy
25		immediately before the due date of the defaulted premium, subject to
26		any provisions endorsed hereon or attached hereto in connection with
27		the reinstatement. Any premium accepted in connection with a
28		reinstatement shall be applied to a period for which premium has not
29		been previously paid, but not to any period more than 60 days prior to
30		the date of reinstatement.
31		(The last sentence of the above provision may be omitted from any
32		policy which the insured has the right to continue in force subject to its
33		terms by the timely payment of premiums:
34		a. Until at least age 50 or,
35		b. In the case of a policy issued after age 44, for at least five years
36		from its date of issue.)
37	(5)	A provision in the substance of the following language:
38		NOTICE OF CLAIM: Written notice of claim must be given to the
39		insurer within 20 days after the occurrence or commencement of any
40		loss covered by the policy, or as soon thereafter as is reasonably
41		possible. Notice given by or on behalf of the insured or the beneficiary
42		to the insurer at (insert the location of such office as the insurer
43		may designate for the purpose), or to any authorized agent of the

1	1993	GENERAL ASSEMBLY OF NORTH CAROLINA
1 2		insurer, with information sufficient to identify the insured, shall be deemed notice to the insurer.
3 4		(In a policy providing a loss-of-time benefit which may be payable for at least two years, an insurer may at its option insert the following
5 6		between the first and second sentences of the above provision:
7		Subject to the qualifications set forth below, if the insured suffers loss of time on account of disability for which indemnity
8 9		may be payable for at least two years, he shall, at least once in every six months after having given notice of claim, give to the
10		insurer notice of continuance of said disability, except in the
11 12		event of legal incapacity. The period of six months following any filing of proof by the insured or any payment by the insurer
13 14		on account of such claim or any denial of liability in whole or in part by the insurer shall be excluded in applying this provision.
15		Delay in the giving of such notice shall not impair the insured's
16		right to any indemnity which would otherwise have accrued
17		during the period of six months preceding the date on which
18 19	(6)	such notice is actually given.)
19 20	(6)	A provision in the substance of the following language: CLAIM FORMS: The insurer, upon receipt of a notice of claim,
20		will furnish to the claimant such forms as are usually furnished by it
22		for filing proofs of loss. If such forms are not furnished within 15 days
23		after the giving of such notice the claimant shall be deemed to have
24		complied with the requirements of this policy as to proof of loss upon
25		submitting, within the time fixed in the policy for filing proofs of loss,
26		written proof covering the occurrence, the character and the extent of
27		the loss for which claim is made.
28	(7)	
29		PROOFS OF LOSS: Written proof of loss must be furnished to the
30		insurer at its said office in case of claim for loss for which this policy
31		provides any periodic payment contingent upon continuing loss within
32 33		90 days after the termination of the period for which the insurer is lighter and in area of alaim for any other loss within 00 days after the
33 34		liable and in case of claim for any other loss within 90 days after the date of such loss. Failure to furnish such proof within the time required
35		shall not invalidate nor reduce any claim if it was not reasonably
36		possible to give proof within such time, provided such proof is
37		furnished as soon as reasonably possible and in no event, except in the
38		absence of legal capacity, later than one year from the time proof is
39		otherwise required.
40	(8)	*
41	. ,	TIME OF PAYMENT OF CLAIMS: Indemnities payable under
42		this policy for any loss other than loss for which this policy provides
43		any period payment will be paid immediately upon receipt of due
44		written proof of such loss. Subject to due written proof of loss, all

accrued indemnities for loss for which this policy provides periodic payment will be paid (insert period for payment which must not be less frequently than monthly) and any balance remaining unpaid upon the termination of liability will be paid immediately upon receipt of due written proof.

(9) A provision in the substance of the following language:

PAYMENT OF CLAIMS: Indemnity for loss of life will be payable in accordance with the beneficiary designation and the provisions respecting such payment which may be prescribed herein and effective at the time of payment. If no such designation or provision is then effective, such indemnity shall be payable to the estate of the insured. Any other accrued indemnities unpaid at the insured's death may, at the option of the insurer, be paid either to such beneficiary or to such estate. All other indemnities will be payable to the insured.

(The following provisions, or either of them, may be included with the foregoing provision at the option of the insurer:

If any indemnity of this policy shall be payable to the estate of the insured, or to an insured or beneficiary who is a minor or otherwise not competent to give a valid release, the insurer may pay such indemnity, up to an amount not exceeding \dots (insert an amount which shall not exceed <u>one_three_thousand dollars (\$1,000) (\$3,000)</u>), to any relative by blood or connection by marriage of the insured or beneficiary who is deemed by the insurer to be equitably entitled thereto. Any payment made by the insurer in good faith pursuant to this provision shall fully discharge the insurer to the extent of such payment.

Subject to any written direction of the insured in the application or otherwise all or a portion of any indemnities provided by this policy on account of hospital, nursing, medical, or surgical services, may at the insurer's option and unless the insured requests otherwise in writing not later than the time of filing proofs of such loss, be paid directly to the hospital or person rendering such services; but it is not required that the service be rendered by a particular hospital or person.)

1 2

3

4 5

6

7

8

9

10

11 12

13

14 15

16

17

18

19

20

21

22

23 24

25

26 27

28 29

30

31

32

33

34 35

36

37

38 39

40

41

42

43 44 (10) A provision in the substance of the following language:

PHYSICAL EXAMINATIONS AND AUTOPSY: The insurer at its own expense shall have the right and opportunity to examine the person of the insured when and as often as it may reasonably require during the pendency of a claim hereunder and to make an autopsy in case of death where it is not forbidden by law.

(11) A provision in the substance of the following language:

LEGAL ACTIONS: No action at law or in equity shall be brought to recover on this policy prior to the expiration of 60 days after written proof of loss has been furnished in accordance with the requirements

1993	GENERAL ASSEMBLY OF NORTH CAROLINA
	of this policy. No such action shall be brought after the expiration of
	three years after the time written proof of loss is required to be
(12	furnished.
(12	2) A provision in the substance of the following language: CHANGE OF BENEFICIARY: Unless the insured makes an
	irrevocable designation of beneficiary, the right to change of
	beneficiary is reserved to the insured and the consent of the beneficiary
	or beneficiaries shall not be requisite to surrender or assignment of this
	policy or to any change of beneficiary or beneficiaries, or to any other
	changes in this policy.
	(The first clause of this provision, relating to the irrevocable
	designation of beneficiary, may be omitted at the insurer's option.)"
	Sec. 4.1. Article 51 of Chapter 58 of the General Statutes is amended
	by adding the following new section to read:
	Coverage of certain prescribed drugs for cancer treatment.
	policy or contract of accident or health insurance, and no preferred
*	ract, policy, or plan as defined and regulated under G.S. 58-50-50 and G.S.
	at is issued, renewed, or amended on or after January 1, 1994, and that
	verage for prescribed drugs approved by the federal Food and Drug
	on for the treatment of certain types of cancer shall exclude coverage of
	the basis that the drug has been prescribed for the treatment of a type of
	which the drug has not been approved by the federal Food and Drug
	on. The drug, however, must be approved by the federal Food and Drug on and must be recognized for the treatment of the specific type of cancer
	drug has been prescribed in any one of the following established reference
<u>compendia:</u>	and has been presented in any one of the following established reference
(1)	The American Medical Association Drug Evaluations;
$\overrightarrow{(2)}$	The American Hospital Formulary Service Drug Information; or
$\overline{(3)}$	
	by review article or editorial comment in a major peer-reviewed
	professional journal published in the United States.
• •	twithstanding subsection (a) of this section, coverage shall not be required
• 1	imental or investigational drugs or any drug that the federal Food and Drug
	on has determined to be contraindicated for treatment of the specific type of
	hich the drug has been prescribed.
	is section shall apply only to cancer drugs and nothing in this section shall
	expressly or by implication, to create, impair, alter, limit, notify, enlarge,
	prohibit reimbursement for drugs used in the treatment of any other disease
or condition.'	
	c. 4.2. Article 54 of Chapter 58 of the General Statutes is amended by
	llowing new section to read:
	Coverage of certain prescribed drugs for cancer treatment. policy that is issued, renewed, or amended on or after January 1, 1994,
	ides coverage for prescribed drugs approved by the federal Food and Drug
and mat DIOV	

1	
	Administration for the treatment of certain types of cancer shall exclude coverage of
2	any drug on the basis that the drug has been prescribed for the treatment of a type of
3	cancer for which the drug has not been approved by the federal Food and Drug
4	Administration. The drug, however, must be approved by the federal Food and Drug
5	Administration and must be recognized for the treatment of the specific type of cancer
6	for which the drug has been prescribed in any one of the following established reference
7	compendia:
8	(1) The American Medical Association Drug Evaluations;
9	(2) The American Hospital Formulary Service Drug Information; or
10	(3) The United States Pharmacopeia Drug Information; or recommended
11	by review article or editorial comment in a major peer-reviewed
12	professional journal published in the United States.
13	(b) Notwithstanding subsection (a) of this section, coverage shall not be required
14	for any experimental or investigational drugs or any drug that the federal Food and Drug
15	Administration has determined to be contraindicated for treatment of the specific type of
16	cancer for which the drug has been prescribed.
17	(c) This section shall apply only to cancer drugs and nothing in this section shall
18	be construed, expressly or by implication, to create, impair, alter, limit, notify, enlarge,
19	abrogate, or prohibit reimbursement for drugs used in the treatment of any other disease
20	or condition."
21	Sec. 4.3. Article 65 of Chapter 58 of the General Statutes is amended by
22	adding the following new section to read:
23	" <u>§ 58-65-93. Coverage of certain prescribed drugs for cancer treatment.</u>
24	(a) No insurance certificate or subscriber contract under any hospital service plan
25	or medical service plan governed by this Article and Article 66 of this Chapter, and no
	preferred provider contract, policy, or plan as defined and regulated under G.S. 58-50-
26	
27	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994,
27 28	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug
27 28 29	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of
27 28 29 30	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of
27 28 29 30 31	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug
27 28 29 30 31 32	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug
27 28 29 30 31 32 33	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer
27 28 29 30 31 32 33 34	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference
 27 28 29 30 31 32 33 34 35 	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia:
 27 28 29 30 31 32 33 34 35 36 	50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations;
 27 28 29 30 31 32 33 34 35 36 37 	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or
27 28 29 30 31 32 33 34 35 36 37 38	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or (3) The United States Pharmacopeia Drug Information; or recommended
 27 28 29 30 31 32 33 34 35 36 37 38 39 	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or (3) The United States Pharmacopeia Drug Information; or recommended by review article or editorial comment in a major peer-reviewed
27 28 29 30 31 32 33 34 35 36 37 38 39 40	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or (3) The United States Pharmacopeia Drug Information; or recommended by review article or editorial comment in a major peer-reviewed professional journal published in the United States.
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or (3) The United States Pharmacopeia Drug Information; or recommended by review article or editorial comment in a major peer-reviewed professional journal published in the United States. (b) Notwithstanding subsection (a) of this section, coverage shall not be required
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or (3) The United States Pharmacopeia Drug Information; or recommended by review article or editorial comment in a major peer-reviewed professional journal published in the United States. (b) Notwithstanding subsection (a) of this section, coverage shall not be required for any experimental or investigational drugs or any drug that the federal Food and Drug
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	 50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug Administration for the treatment of certain types of cancer shall exclude coverage of any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for which the drug has not been approved by the federal Food and Drug Administration. The drug, however, must be approved by the federal Food and Drug Administration and must be recognized for the treatment of the specific type of cancer for which the drug has been prescribed in any one of the following established reference compendia: (1) The American Medical Association Drug Evaluations; (2) The American Hospital Formulary Service Drug Information; or (3) The United States Pharmacopeia Drug Information; or recommended by review article or editorial comment in a major peer-reviewed professional journal published in the United States. (b) Notwithstanding subsection (a) of this section, coverage shall not be required

1993

1	(c) This section shall apply only to cancer drugs and nothing in this section shall
2	be construed, expressly or by implication, to create, impair, alter, limit, notify, enlarge,
3	<u>abrogate, or prohibit reimbursement for drugs used in the treatment of any other disease</u>
4	or condition."
5	Sec. 4.4. Article 67 of Chapter 58 of the General Statutes is amended by
6	adding the following new section to read:
7	"§ 58-67-77. Coverage of certain prescribed drugs for cancer treatment.
8	(a) No health care plan written by a health maintenance organization and in
9	force, issued, renewed, or amended on or after January 1, 1994, and that provides
10	coverage for prescribed drugs approved by the federal Food and Drug Administration
11	for the treatment of certain types of cancer shall exclude coverage of any drug on the
12	basis that the drug has been prescribed for the treatment of a type of cancer for which
13	the drug has not been approved by the federal Food and Drug Administration. The
14	drug, however, must be approved by the federal Food and Drug Administration and
15	must be recognized for the treatment of the specific type of cancer for which the drug
16	has been prescribed in any one of the following established reference compendia:
17	(1) The American Medical Association Drug Evaluations;
18	(2) The American Hospital Formulary Service Drug Information; or
19	(3) The United States Pharmacopeia Drug Information; or recommended
20	by review article or editorial comment in a major peer-reviewed
21	professional journal published in the United States.
22	(b) Notwithstanding subsection (a) of this section, coverage shall not be required
23	for any experimental or investigational drugs or any drug that the federal Food and Drug
24	Administration has determined to be contraindicated for treatment of the specific type of
25	cancer for which the drug has been prescribed.
26	(c) This section shall apply only to cancer drugs and nothing in this section shall
27	be construed, expressly or by implication, to create, impair, alter, limit, notify, enlarge,
28	abrogate, or prohibit reimbursement for drugs used in the treatment of any other disease
29	or condition.
30	Sec. 4.5. Article 50 of Chapter 58 of the General Statutes is amended by
31	adding the following new section to read:
32	" <u>§ 58-50-156. Coverage of certain prescribed drugs for cancer treatment.</u>
33	(a) Notwithstanding G.S. 58-50-125(c), if the standard health plan developed and
34	approved under G.S. 58-50-125 provides coverage for prescribed drugs approved by the
35	federal Food and Drug Administration for the treatment of certain types of cancer, then
36	coverage may not be excluded for any drug on the basis that the drug has been
37	prescribed for the treatment of a type of cancer for which the drug has not been
38	approved by the federal Food and Drug Administration. Coverage for such drugs shall
39	be as required under G.S. 58-51-58."
40	Sec. 5. This act becomes effective October 1, 1993.